Sutro Biopharma (NASDAQ:STRO) — Market Cap & Net Worth
Market Cap & Net Worth: Sutro Biopharma (STRO)
Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $79.09 Million ($79.09 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20006 globally and #4501 in its home market, demonstrating a 2.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sutro Biopharma's stock price $24.17 by its total outstanding shares 85135290 (85.14 Million). See STRO capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Sutro Biopharma Market Cap History: 2018 to 2026
Sutro Biopharma's market capitalization history from 2018 to 2026. Data shows growth from $767.92 Million to $2.06 Billion (6.09% CAGR).
Index Memberships
Sutro Biopharma is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #566 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1929 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.00% | #245 of 263 |
Weight: Sutro Biopharma's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sutro Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sutro Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.52x
Sutro Biopharma's market cap is 2.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $767.92 Million | $38.42 Million | -$35.32 Million | 19.99x | N/A |
| 2019 | $936.49 Million | $42.74 Million | -$55.74 Million | 21.91x | N/A |
| 2020 | $1.85 Billion | $42.72 Million | -$32.13 Million | 43.26x | N/A |
| 2021 | $1.27 Billion | $61.88 Million | -$105.54 Million | 20.47x | N/A |
| 2022 | $687.89 Million | $67.77 Million | -$119.20 Million | 10.15x | N/A |
| 2023 | $365.23 Million | $153.73 Million | -$106.79 Million | 2.38x | N/A |
| 2024 | $156.65 Million | $62.04 Million | -$227.46 Million | 2.52x | N/A |
Competitor Companies of STRO by Market Capitalization
Companies near Sutro Biopharma in the global market cap rankings as of August 3, 2026.
Key companies related to Sutro Biopharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Sutro Biopharma Historical Marketcap From 2018 to 2026
Between 2018 and today, Sutro Biopharma's market cap moved from $767.92 Million to $ 2.06 Billion, with a yearly change of 6.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.06 Billion | +108.90% |
| 2025 | $985.02 Million | +528.80% |
| 2024 | $156.65 Million | -57.11% |
| 2023 | $365.23 Million | -46.91% |
| 2022 | $687.89 Million | -45.70% |
| 2021 | $1.27 Billion | -31.46% |
| 2020 | $1.85 Billion | +97.36% |
| 2019 | $936.49 Million | +21.95% |
| 2018 | $767.92 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Sutro Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $79.09 Million USD |
| MoneyControl | $79.09 Million USD |
| MarketWatch | $79.09 Million USD |
| marketcap.company | $79.09 Million USD |
| Reuters | $79.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid … Read more